Based on the present data, considering the high expression of OCT4, Sox-2, Nanog, and lin28 embryonic stem cell marker, MSCs derived from cord blood are proposed as a more appropriate candidate for cellular therapy compared to MSCs derived from the bone marrow and AD. This evidence concerns the gene SOX2 and Alzheimer disease.